2',3'-dideoxyinosine — Competitive Intelligence Brief

2',3'-dideoxyinosine (2',3'-dideoxyinosine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI). Area: Infectious Disease / Virology.

phase 3 Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule

Target snapshot

2',3'-dideoxyinosine (2',3'-dideoxyinosine) — National Cancer Institute (NCI). 2',3'-dideoxyinosine (ddI) is a nucleoside reverse transcriptase inhibitor that blocks HIV replication by inhibiting the enzyme responsible for converting viral RNA into DNA.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
2',3'-dideoxyinosine TARGET	2',3'-dideoxyinosine	National Cancer Institute (NCI)	phase 3	Nucleoside reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase
Ritonavir boosted Atazanavir + Lamivudine	Ritonavir boosted Atazanavir + Lamivudine	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitor)	HIV protease; HIV reverse transcriptase
Rilpivirine + darunavir/cobicistat	Rilpivirine + darunavir/cobicistat	A.O. Ospedale Papa Giovanni XXIII	marketed	Antiretroviral combination (NNRTI + protease inhibitor + pharmacokinetic booster)	HIV reverse transcriptase, HIV protease
Ritonavir boosted Atazanavir + 2 NRTIs	Ritonavir boosted Atazanavir + 2 NRTIs	Fundacion SEIMC-GESIDA	marketed	Protease inhibitor combination antiretroviral therapy	HIV protease, HIV reverse transcriptase
TAF/FTC FDC	TAF/FTC FDC	Janssen Scientific Affairs, LLC	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase
Tenofovir disoproxil/emtricitabine/rilpivirine	Tenofovir disoproxil/emtricitabine/rilpivirine	Sheba Medical Center	marketed	Antiretroviral combination (NRTI + NNRTI)	HIV reverse transcriptase
tenofovir + abacavir + efavirenz	tenofovir + abacavir + efavirenz	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) class)

1. French National Agency for Research on AIDS and Viral Hepatitis · 3 drugs in this class
2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
3. ViiV Healthcare · 2 drugs in this class
4. Nanfang Hospital, Southern Medical University · 2 drugs in this class
5. Asan Medical Center · 1 drug in this class
6. Dong-A ST Co., Ltd. · 1 drug in this class
7. Bristol-Myers Squibb · 1 drug in this class
8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
9. Fu-Sheng Wang · 1 drug in this class
10. Avexa · 1 drug in this class